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Characterization of tubular functional capacity in humans using in impaired hydrogen homeostasis, altered hormone syn-
para-aminohippurate and famotidine. thesis and metabolism, reduced secretion of organic sol-
Background. Renal drug excretion by glomerular filtration utes (anionic and cationic), and disorders of water, so-and active tubular secretion may be altered by factors such
dium, and urea balance [1, 2]. Renal tubular injury oftenas acute and chronic renal disease, nephrotoxins, and drug
precedes glomerular injury and is a strong predictor ofinteractions. Thus, accurate and reproducible methods for
quantitation of glomerular filtration rate (GFR) and tubular progressive renal disease [3, 4]. Although acute tubular
functional capacity are critical. injury has been characterized by dramatic increase in
Methods. We utilized a four-step sequential infusion method
the renal excretion of intracellular tubular enzymes suchto characterize anionic [para-aminohippurate (PAH)] and cat-
as b2-microglobulin and N-acetyl-b-D-glucosaminidaseionic (famotidine) tubular functional capacity in healthy volun-
teers. Filtration and secretion rates were quantitated from renal (NAG), these measurements do not provide a quantita-
clearance and iothalamate-derived GFR determinations. tive measure of the degree of residual renal function
Results. Concentration-dependent renal clearance of PAH [5, 6]. Progressive changes in tubular function have beenwas observed at plasma concentrations .100 mg/L; renal clear-
associated with a reduction in urinary concentrating ca-ances were 442 6 131 (mean 6 SD), 423 6 94, 233 6 45, and
pacity (that is, specific gravity and urinary sodium con-152 6 18 mL/min/1.73 m2 at plasma concentrations of 18 6 2,
92 6 5, 291 6 47 and 789 6 28 mg/L, respectively. The apparent centration), the threshold for tubular glucose reabsorp-
affinity (Km) and maximum secretory capacity (TmPAH) were tion, and an increase in fractional excretion of sodium
141 6 70 mg/L and 71 6 16 mg/min/1.73 m2, respectively. The
(FENa), magnesium (FEMg), or lithium (FELi) [7]. Theseunbound renal clearance and tubular secretory clearance of
indices are often confounded by variability in urine flowfamotidine were 384 6 70 and 329 6 78 mL/min/1.73 m2, respec-
tively, and were not significantly correlated with the unbound rates, hydration status, and concurrent drug therapy.
plasma concentrations, which ranged from 126 to 2659 ng/mL. The capacity-limited renal handling of para-aminohip-
The rate of tubular secretion was linear at unbound plasma purate (PAH) has been extensively studied in basolateralconcentrations up to 2659 ng/mL.
membrane vesicles [8], Xenopus laevis oocytes [9, 10],Conclusions. These data indicate that a sequential infusion
and opossum kidney cell monolayers [11] and in beaglemethod using PAH may be used to characterize the anionic
secretory component of proximal tubular function. The tubular dogs [12]. Cationic tubular secretion has been studied
clearance of famotidine may be a suitable index of the cationic using organic cations such as cimetidine and famotidine
secretory capacity of the proximal tubule in humans. Saturation
in dog [13] and human [14] brush-border membrane vesi-of the cationic secretory pathway was not observed, and further
cles and in isolated proximal tubular cells [15]. Saturationinvestigation into parallel pathways of cationic secretion, such
as p-glycoprotein, may be warranted. of the cationic pathway using famotidine has been dem-
onstrated in intact rats [16] and dogs [17], but this re-
mains to be investigated in humans.
Chronic renal insufficiency is often associated with renal In patients with a history of chronic alcoholism and
tubular as well as glomerular dysfunction, which can result biochemical evidence of mild liver disease with normal
renal function [glomerular filtration rate (GFR) 95 6 21
mL/min/1.73 m2], tubular defects such as reduced glucoseKey words: renal tubular secretion, organic anion, cation, famotidine,
p-glycoprotein. reabsorptive capacity, renal threshold for phosphate ex-
cretion, and increased proximal tubular enzymuria (NAG
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and alanine aminopeptidase) were observed [18]. Thisand in revised form June 12, 2000
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precise, and minimally invasive quantitation methods sis. Urine was collected at baseline and after spontaneous
voiding in each of the three 30-minute intervals through-are needed to assess tubular function in humans. The
development of these new tools may aid in the elucida- out the four 90-minute evaluation periods; the total vol-
ume of each collection was recorded, and aliquots weretion of the mechanisms of various types of renal diseases
and nephrotoxic injury. stored at 2208C until analyzed.
To characterize proximal tubular function in humans
Famotidine clearance studyrigorously, PAH and famotidine were chosen as the pro-
totypical anionic and cationic substrates, respectively. Subjects were admitted to the General Clinical Re-
search Center the morning after a 12-hour overnight fast.The present study was designed to explore the utility of
characterizing the renal elimination and tubular clear- They continued to fast throughout the study evaluation
period. Intravenous catheters were placed in each fore-ance of these substrates of anionic and cationic tubular
secretion, respectively, in humans using an efficient se- arm, and subjects remained in a semireclined position
except during voiding. Oral water loading was followedquential infusion method.
by initiation of the iothalamate priming dose and infu-
sion as described previously in this article.
METHODS
A priming dose (0.25 mg/kg) of famotidine (Merck) was
Study population followed by a 2.5-hour intravenous infusion (5 mg/hour)
designed to achieve plasma concentrations of 100 toNormal healthy male volunteers were recruited to par-
ticipate in this study, which was approved by the Univer- 250 ng/mL. After 2.5 hours, the subject was rebolused
(0.5 mg/kg), and the infusion was increased (20 mg/hour)sity of Pittsburgh Biomedical Institutional Review Board.
All subjects provided written informed consent prior to to achieve plasma concentrations of 300 to 750 ng/mL
(step 2). Subsequent priming doses of 0.78 and 1.2 mg/kgscreening, which included a review of past medical his-
tory, physical examination, urinalysis, and biochemical followed by 2.5-hour infusions of 60 and 120 mg/hour
were administered to achieve plasma concentrations ofprofile. Normal renal function was confirmed by an ambu-
latory 24-hour creatinine clearance (CCr) measurement 800 to 1300 (step 3) and 2000 to 2750 ng/mL (step 4),
respectively. Blood and urine samples were collected,performed within one week prior to the first randomized
study visit. The two ten-hour visits were separated by a processed, and stored as described previously in this
article.minimum of seven days.
PAH clearance study Bioanalytical methods
Plasma and urine concentrations of iothalamate, PAH,Subjects were admitted to the General Clinical Re-
search Unit of the University of Pittsburgh Medical Cen- and its acetyl metabolite, acetyl-PAH (aPAH), were de-
termined using a reversed-phase high-performance liq-ter the morning after an overnight (12 h) fast; subjects
continued to fast throughout the study evaluation period. uid chromatography (HPLC) method [19] with minor
modifications. The lower limits of quantitation in plasmaFollowing placement of an intravenous catheter in each
forearm, subjects remained in a semireclined position and urine were 5.0, 5.0, and 1.0 mg/L and 50.0, 100.0,
20.0 mg/L for iothalamate and PAH and aPAH, respec-except during voiding. Each subject received an oral
water load (750 mL over 45 minutes) and a priming dose tively. Within- and between-day coefficients of variation
for plasma and urine determinations were less than 5%.of iothalamate (1 mL Conray-30; Mallinkrodt, St. Louis,
MO, USA) over two to three minutes at approximately Concentrations of famotidine in plasma and urine
were determined using HPLC [20]. The reference stan-9 a.m. The maintenance dose of iothalamate (mg/hour)
required to maintain a steady-state plasma concentration dard concentrations in plasma and urine ranged from
75.0 to 1500 ng/mL and 1 to 20 mg/mL, respectively. Theof 30 mg/L over the entire study period was based on
each subject’s 24-hour CCr. The infusion volume was kept within-day coefficients of variation for quality control
samples ranged from 5.7 to 9.9% in plasma and 1.3 toconstant by adjusting the concentration of iothalamate
in the infusate. 2.6% in urine. The between-day coefficients of variation
for quality control samples ranged from 9.0 to 10.5% inPara-aminohippurate (20% solution; Merck, West-
point, PA, USA) was administered as a series of priming plasma and 3.4 to 9.5% in urine.
The fraction of famotidine bound to plasma proteinsdoses followed by sequential 2.5-hour intravenous infu-
sions designed to achieve plasma concentrations of 15 was determined from samples collected during each infu-
sion level; 1.0 mL of plasma was placed in a Centrifreeto 20 (step 1), 70 to 100 (step 2), 200 to 500 (step 3),
and 700 to 900 mg/L (step 4), respectively. Heparinized micropartition device (Amicon, Beverly, MA, USA) and
spun at (1500 3 g) for 60 minutes in a temperature-blood samples (10 mL) were obtained at baseline and
every 30 minutes throughout the study; plasma was sepa- controlled centrifuge. The free concentration of famoti-
dine in plasma ([Cpu]) was calculated as [Cpu] 5 [Cp] 3rated by centrifugation and stored at 2208C until analy-
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fu, where [Cp] is total plasma concentration and fu is (ANOVA) model with interval as the main effect and
the free fraction of famotidine in plasma. Binding of subjects as a random effect using SAS version 6.12 (SAS
PAH to plasma proteins was not determined in these Institute, Cary, NC, USA). Plasma and renal clearances
subjects and assumed to be zero since it is low with values of PAH at step 1 were compared using Wilcoxon signed
ranging from 2.4% in sheep [21] to 12% in humans [22]. rank for paired observations, and the relationship be-
Creatinine concentrations in plasma and urine were de- tween the famotidine Rsec and [Cpu] was assessed by
termined by an enzymatic method using the VITROSt linear regression (GraphPad Software, Inc., San Diego,
Chemistry System (Johnson & Johnson Clinical Diag- CA, USA). Data are presented as mean 6 SD. A P value
nostics, Rochester, NY, USA). of less than 0.05 was considered statistically significant.
Pharmacokinetic analysis
RESULTSThe total body clearance of PAH and famotidine was
Five healthy males who had a mean age and weightcalculated as the dose delivered over the last 90 minutes
of 25 6 4 years (mean 6 SD) and 77 6 12 kg, respectively,of the infusion, divided by the average steady-state
participated in this study. The prestudy serum creatinineplasma concentration (Cpave) achieved during the infu-
and 24-hour CCr values were 1.1 6 0.1 mg/dL and 92 6sion. The nonrenal clearance (CNR) of PAH and famoti-
8 mL/min/1.73 m2, respectively. The baseline GFR ofdine was calculated as CTOT minus CR (total clearance
these subjects during the PAH and famotidine evalua-minus renal clearance). The unbound renal clearance
tions was 87 6 13 and 90 6 18 mL/min/1.73 m2, respec-was calculated as the mean of the three 30-minute values:
tively. Intraday coefficients of variation for the GFR
CR 5 Au/AUC determinations were 13 and 12% for the PAH and famo-
tidine evaluations, respectively.where Au is the amount recovered in urine, and AUC
is the area under the unbound plasma concentration-
PAH clearance studyversus-time curve for the 90-minute collection interval
Five subjects were evaluated at target PAH plasmacalculated by the linear trapezoidal rule [23]. The filtration
concentrations of 15 to 20 mg/L (step 1), 70 to 100 mg/Lfraction (FF%) was calculated as 100 3 GFR/PAH CR.
(step 2), and 700 to 900 mg/L (step 4), and three subjectsThe rate of tubular secretion (Rsec) of PAH and famoti-
were evaluated at target PAH plasma concentrations ofdine was calculated as follows:
200 to 500 mg/L (step 3). The urine flow rate and urine
Rsec 5 Rexc 2 (GFR 3 [Cpu]) pH (mean 6 SD) during the clearance studies were 12 6
4 mL/min and 5.8 6 0.9, respectively. The plasma concen-where Rexc is the rate of urinary PAH excretion during
trations of PAH and aPAH observed during each ofeach 30-minute interval, and [Cpu] is the average un-
bound concentration of PAH or famotidine in plasma. the four step-up infusions are shown in Figure 1. Two
Rsec and [Cpu] data for PAH and famotidine were fit to subjects reported a slight warming sensation during the
the Tmax model: administration of the highest priming dose (150 to 200
mg/min), which resolved within 5 to 10 minutes after
administration.Rsec 5
(TmPAH 3 Cpu)
(Km 1 Cpu)
PAHwhere TmPAH is the maximum rate of tubular secretion,
The plasma clearance of PAH during step 1 was sig-and Km is the plasma concentration at half-maximal se-
nificantly greater than renal clearance (510 6 95 vs. 442 6cretion rate. The TmPAH and Km values were estimated
131 mL/min/1.73 m2, P 5 0.03). The nonrenal clearanceusing nonlinear regression. (PCNONLIN; Pharsight Corp.,
of PAH during step 1 was 68 6 47 mL/min/1.73 m2 andMountain View, CA, USA). Intrinsic clearance (IC) was
averaged 14.6 6 12.4% of plasma clearance. The percent-calculated as TmPAH divided by Km.
age of the PAH dose excreted as PAH and aPAH duringThe tubular clearance of PAH and famotidine was cal-
the last 90 minutes of the infusion was 80 6 19% and 9 6culated as CTUB 5 CR 2 CFILT, where CR is renal clearance,
2.6%, respectively. The renal clearance values for PAHand CFILT is filtration clearance calculated as GFR 3 fu.
are reported in Table 1 and are illustrated in Figure 2A.
Statistical analysis The renal clearance of PAH at step 1 was not significantly
different from that in step 2 (P 5 0.98). The filtrationThe renal clearances of famotidine, iothalamate, PAH,
fraction values ranged from 16.4 to 28.3%. The renaland aPAH for each subject were normalized to 1.73 m2
clearance at step 3 was lower than step 2 (P 5 0.06), andbody surface area (BSA). Comparisons of clearance val-
the difference became highly significant when comparedues at each of the four infusion steps were made using
a mixed effects repeated-measures analysis of variance with step 4 (P 5 0.001). The renal clearance at step 3 was
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Table 1. Para-aminohippurate (PAH), acetyl-PAH (aPAH) and
iothalamate data obtained during sequential infusions
Subject GFR Step Cpu mg/L RSEC CR, PAH CR,aPAH
101 98 1 15.0 6.4 596 850
100 2 87.2 38.5 548 403
79 4 753.9 71.1 130 78
102 75 1 20.2 3.9 265 402
79 2 93.2 24.9 358 313
80 3 238.3 47.1 285 218
86 4 805.3 47.7 141 88
103 65 1 20.1 5.1 360 443
72 2 92.5 25.0 305 275
71 3 329.8 40.1 204 142
68 4 763.2 70.8 174 128
104 114 1 17.6 6.8 475 747
100 2 99.1 37.0 449 385
97 4 813.3 48.2 164 108
105 95 1 16.8 6.8 515 622
92 2 87.2 31.6 457 348
84 3 304.8 34.5 209 144
88 4 808.2 55.3 154 91
Mean (SD)
Step 1 89 (20) 18 (2) 6 (1) 442 (131) 613 (192)
Step 2 89 (14) 92 (5) 31 (6) 423 (94) 345 (53)d
Step 3 78 (6) 291 (47) 41 (6) 233 (45)a 168 (43)e
Step 4 84 (12) 789 (28) 59 (12) 152 (18)bc 99 (20)fg
All mean clearance values are in mL/min/1.73 m2.
aP 5 0.03 vs. PAH step 1
b P 5 0.008 vs. PAH step 1
c P 5 0.001 vs. PAH step 2
d P 5 0.008 vs. aPAH step 1
e P 5 0.001 vs. aPAH step 1
f P 5 0.0001 vs. aPAH step 1
g P 5 0.01 vs. aPAH step 2
Fig. 1. Plasma concentration versus time profile (mean 6 SD) corre- PAH concentration is depicted in Figure 3. The averagesponding to the sequential para-aminohippuride (PAH) infusions (steps
fitted maximal rate of tubular secretion (TmPAH) was 71 61 through 4) for PAH (A) and acetyl-PAH (aPAH; B).
16 mg/min/1.73 m2, and the apparent affinity (Km) was
141 6 70 mg/L, yielding an IC of 34 6 10 L/h. The
median coefficients of variation for the model estimatesslightly higher (233 6 45 vs. 152 6 18 mL/min/1.73 m2)
(TmPAH and Km) were 8% (range, 5 to 21%) and 20%but not significantly different from step 4 (P 5 0.39).
(range, 6 to 60%), respectively; the median r2 value for
the nonlinear model was 0.93 (range, 0.84 to 0.99).Acetyl-PAH
When PAH plasma concentrations ranged from 15 to Famotidine clearance study
20 mg/L (step 1), the aPAH plasma concentrations were
Five subjects were evaluated at the first and second1.5 6 0.3 mg/L, and the renal clearance of aPAH ex-
target concentrations, while three subjects were evalu-ceeded the renal clearance of PAH in all subjects (613 6
ated at unbound famotidine plasma concentrations of192 vs. 442 6 131 mL/min/1.73 m2, P 5 0.06). The renal
800 to 1300 or 2000 to 2750 ng/mL. The average urineclearance of aPAH was significantly reduced to 345 6
flow rate and urine pH during the clearance studies were52 mL/min/1.73 m2 (P 5 0.008) during the step 2 infusion.
13 6 2 mL/min and 5.5 6 0.8, respectively. The unboundThe renal clearance of aPAH progressively declined as
plasma concentrations of famotidine attained duringsystemic PAH and aPAH levels increased (Fig. 2B) and
each infusion are reported in Table 2. No adverse experi-approached GFR. The value at step 2 was similar to that
ences were reported by the study subjects.of step 3 (P 5 0.2), while the step 4 value was significantly
The percentage of famotidine bound to plasma pro-lower (P 5 0.01). The renal clearance at steps 3 and 4,
teins was 39 6 1% and concentration independent. Thehowever, was not different from each other (P 5 0.66;
CTOT at steps 1 through 4 was 592 6 91, 683 6 203, 787 6Fig. 2B).
88, and 733 6 93 mL/min/1.73 m2, respectively. The CR
Characterization of PAH tubular secretion was 350 6 97 mL/min/1.73 m2 during step 1 and remained
unchanged (P . 0.05) over the range of plasma concen-The individual values for rate of secretion are shown
in Table 1. The relationship between Rsec and plasma trations achieved for each subject (Table 2). The CNR
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tubule anionic secretory pathway (Km and TmPAH). The
unbound renal clearance and CTUB of famotidine were
stable over a 25-fold range of plasma concentrations. The
assessment of famotidine CTUB may thus be used as an
index of cationic tubular secretion in humans. Saturation
of the cationic pathway was not evident in the concentra-
tion range evaluated and if present in humans will re-
quire the achievement of higher unbound plasma con-
centrations.
PAH
This study represents the first rigorous characteriza-
tion of the anionic secretory pathway in humans with
PAH. The apparent affinity of PAH for the anionic path-
way was 141 mg/L, which is the first report of Km in
humans. The observed TmPAH of 71 6 16 mg/min/1.73 m2
is similar to that reported by Chasis et al (78 6 13 mg/
min/1.73 m2) [24] and somewhat lower than the recent
observation of 89 6 4 mg/min/1.73 m2 [25]. A lower
TmPAH value (50 mg/min/1.73 m2) derived from a single-
rate PAH infusion in seven healthy renal donors was
observed in an earlier study by Pabico, McKenna, and
Freeman [26]. In that study, TmPAH was calculated at
plasma PAH concentration of approximately 400 mg/L,
which may be insufficient to saturate transport and thereby
adequately characterize TmPAH. The Rsec value we ob-
served at plasma PAH concentration of 400 mg/L (Fig. 3)
is approximately 50 mg/min/1.73 m2 and suggests thatFig. 2. Renal clearance values for PAH (A) and aPAH (B) during
the sequential PAH infusions (steps 1 through 4). The horizontal bar the value reported by Pabico et al was an underestimate
indicates the mean renal clearance at each infusion step, and the stippled due to nonsaturation of the transport pathway [26]. Aline indicates the mean GFR in the study subjects.
potential confounding factor in estimating Km and TmPAH
in this study is circadian rhythm-induced changes in renal
function. Although the effects of circadian rhythm on
tubular function are unknown, a recent study reported nowas 299 6 111 mL/min/1.73 m2, which accounted for 43 6
change in GFR in healthy volunteers during a 24-hour10% of CTOT. The CTUB was 287 6 107, 345 6 81, 351 6
evaluation [27]. Therefore, it is unlikely that our results37, 349 6 42 mL/min/1.73 m2 at steps 1 through 4, respec-
would be confounded by circadian rhythm-inducedtively.
changes in renal function.The relationship between Rsec and unbound famoti-
The intrinsic renal clearance of PAH in the presentdine plasma concentrations is depicted in Figure 4. The
study (34 6 10 L/hour/1.73 m2) reflects the relative effi-tubular secretion of famotidine increased linearly over
ciency of the anionic secretory pathway for this substrate.the range of plasma concentrations achieved during each
Four studies in the past 15 years have assessed anionicinfusion (Table 2), with average Rsec values of 36 6 13,
tubular secretion using sequential infusion methodolo-162 6 38, 381 6 20, and 773 6 24 mg/min/1.73 m2 at
gies: Three used penicillins, and one used a cephalospo-steps 1 through 4, respectively. Thus, the Tmax model was
rin. Benzylpenicillin was investigated as a secretorynot evaluated since a linear relationship was observed
probe by two groups of investigators. The IC derivedbetween Rsec and [Cpu].
from four healthy volunteers was 76 6 23 L/h [28]. In a
subsequent study in six healthy volunteers, the IC was
DISCUSSION 58.7 6 6.8 L/hour [29]. Wang et al reported a lower IC
Para-aminohippurate, aPAH, and famotidine undergo (,13.4 L/h) for ticarcillin in six healthy subjects [30].
extensive tubular secretion in humans. The sequential Verhagen, Mattie, and Van Strijen reported an IC of
PAH infusion methodology allowed us to characterize 8.3 6 2.2 L/h for cefuroxime in five healthy volunteers;
the capacity-limited renal handling of PAH in healthy vol- however, tubular secretion of ceftazidime was found to
unteers. This procedure was well tolerated and provides in be negligible [31]. The variability in IC values for these
secretory probes may be due to differences in the relativevivo estimates of the functional capacity of the proximal
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Fig. 3. Plot of the rate of tubular secretion
(Rsec) relative to the plasma concentration of
PAH in all subjects. Data points represent
mean values 6 SD. The solid line represents
the mean of the fitted values of Km (141 mg/L)
and TmPAH (71 mg/min/1.73 m2).
affinities among substrates, as well as estimation of GFR 1.73 m2, P 5 0.03) than renal clearance and yielded a
mean nonrenal clearance of 68 6 47 mL/min/1.73 m2 orusing CCr rather than measurement with an accepted
standard such as iothalamate. In addition, secretion via 14.6 6 12.4% of plasma clearance. The renal clearance
was stable at plasma concentrations up to 100 mg/L. Thethe H1/cationic antiporter and reabsorption via the H1/
peptide cotransporter has been reported for some b- mean percentage of PAH excreted as aPAH (10.0 6
1.5%, range, 7.2 to 12.4%) was similar to previous reportslactam antibiotics [32, 33]. Use of PAH as the anionic
probe may thus be preferred, since it undergoes exten- of 10.2 6 2.7% [37] and 15.2 6 1.8% [38] obtained
during constant-rate infusion. Thus, plasma clearancesive extraction and avoids the potential of idiosyncratic
or allergic reactions (acute interstitial nephritis) and measurements are a confounded measure of renal func-
tion and may yield uninterpretable data in patients withnephrotoxicity that have been reported with penicillins
and cephalosporins [34]. mild liver disease who may have reduced ability to ace-
tylate PAH (abstract; Dowling et al, Clin PharmacolThe effective renal plasma flow (ERPF) values we
observed in this study (442 6 131 mL/min/1.73 m2) were Ther 67:215, 1997).
The renal clearance of PAH declined significantly aslower than previous reports of 654 6 163 mL/min/1.73 m2
using classic constant-rate infusion techniques targeting plasma concentrations were increased from 100 to 700
mg/L. These results are consistent with previous investi-PAH concentrations of 15 to 20 mg/L [35]. The lower
renal PAH clearance values reported here are likely due to gations of the organic anions phenol red, hippuran, and
diodrast that demonstrated concentration-dependent re-differences in the analytical techniques used to determine
nal clearance [24, 39]. Although renal clearance of PAHPAH concentrations in plasma and urine. Traditional
could be reduced as a result of competition with aPAHcolorimetric methods are unable to distinguish aPAH
for secretion via the anionic pathway, it is unlikely sincefrom PAH in plasma and urine; urinary PAH concentra-
plasma PAH concentrations ranged from 11- and 23-foldtions are thus higher, and plasma PAH concentrations
greater than plasma aPAH concentrations during stepsare lower than the HPLC determinations we utilized. In
3 and 4, respectively. Thus, the concentration-dependentthe only direct comparison, the PAH renal clearance
renal clearance of PAH is likely due to saturation of thevalues based on colorimetric quantitation were approxi-
anionic secretory pathway.mately 35% higher than the clearance values using HPLC
data [36]. The ERPF values in our five males were ap-
Acetyl-PAHproximately 32% lower than the mean ERPF normal
values based on colorimetric analysis and thus support We have shown that the renal clearance of aPAH
also declines as plasma PAH concentrations increase. Atthe previous observations of Decosterd et al [36, 37].
The plasma clearance obtained during the ERPF deter- plasma PAH concentrations of approximately 20 mg/L,
the renal clearance of aPAH exceeded that of the PAHmination was higher (510 6 95 vs. 442 6 131 mL/min/
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Table 2. Famotidine and iothalamate data obtained during sequential infusions
Subject GFR Step Cpu ng/mL RSEC CTOT CR CTUB CNR
201 100 1 140 39 625 380 317 245
97 2 418 146 720 443 382 277
86 3 1039 378 876 378 324 498
88 4 2176 768 836 448 393 388
202 75 1 126 42 715 393 346 322
71 2 475 158 658 386 341 271
71 3 1199 362 784 380 335 404
67 4 2659 800 707 350 308 357
203 87 1 159 35 476 294 239 182
84 2 502 167 530 380 327 150
81 3 1129 402 700 444 393 256
67 4 2410 752 656 389 347 267
204 125 1 137 15 534 216 128 319
119 2 582 117 499 309 225 191
205 116 1 129 48 609 459 404 150
100 2 280 220 1007 495 447 512
Mean (SD)
Step 1 100 (20) 138 (13) 36 (13) 592 (91) 349 (95) 287 (107) 244 (78)
Step 2 94 (18) 451 (113) 162 (38) 683 (203) 405 (70) 344 (81) 280 (140)
Step 3 79 (8) 1122 (80) 381 (20) 787 (88) 400 (39) 351 (37) 386 (122)
Step 4 74 (12) 2415 (242) 773 (24) 733 (93) 414 (30) 349 (43) 337 (63)
All mean clearance values are in mL/min/1.73 m2.
Famotidine
The plasma famotidine concentrations achieved dur-
ing the infusion of 5 mg/h of 138 6 13 ng/mL are similar
to those observed following single-dose oral administra-
tion of 40 mg of famotidine [41–43]. The famotidine
fraction unbound was concentration independent as de-
scribed in previous animal studies (at plasma concentra-
tions up to 50,000 ng/mL) [16, 17]. However, the ob-
served fraction bound (39%) was higher than previous
reports in humans of 10 to 28%, which where determined
by equilibrium dialysis at concentrations up to 500 ng/mL
[41, 44]. There are at least two possible reasons for the
high degree of famotidine binding to plasma proteins we
observed in these subjects: (1) an inherent difference inFig. 4. Relationship between the rate of tubular secretion (Rsec) and
the unbound concentration of famotidine in plasma. Data points indi- the patients and/or (2) the fact that we utilized a filtration
cate the Rsec values obtained during the last 90 minutes of the infusion. method for this determination while in the past equilib-Symbols represent individual subjects. The solid line is the fitted least
squares regression line (y 5 0.37 3 x 2 2.3, r2 5 0.95, P , 0.001). rium dialysis has been used. Although the absolute val-
ues for protein binding are higher in this study popula-
tion, it does not cloud the interpretation of our results.
The renal clearance of famotidine in these subjects(613 6 192 vs. 442 6 131 mL/min/1.73 m2, respectively,
consistently exceeded GFR at plasma concentrations ofP 5 0.01) and is similar to values reported by Prescott,
up to 2659 ng/mL. This is compatible with data from ratsFreestone, and McAuslane (790 6 281 mL/min/1.73 m2)
[16] and dogs [17] where renal clearance was constant[38]. However, at higher PAH concentrations, the renal
at famotidine concentrations up to 4600 and 8700 ng/mL,clearance of aPAH declined to values approaching GFR.
respectively. Saturation of tubular secretion, however,This may be due to changes in intrarenal acetylation
was reported in both species at plasma concentrationsor the result of competitive inhibition with PAH for
greater than 15,000 ng/mL. Plasma concentrations of thissecretion via the anionic pathway. Although intrarenal
degree have not been reported in humans, and the likeli-metabolism of PAH to aPAH has been confirmed in an
hood of saturation in humans remains questionable.isolated perfused rat kidney, the contribution of this to
The total body clearance of famotidine exceeded theCR,aPAH is unknown [40]. Other factors such as the relative
renal clearance values by 41 6 9% indicating nonrenalaffinity of aPAH for the anionic pathway, the relation-
clearance. This is consistent with previous reports ofship between plasma PAH concentration, and the renal
handling of aPAH require further evaluation. nonrenal clearance ranging from 36 to 48% in healthy
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subjects [42, 44, 45]. The unbound tubular clearance of dosing regimens (40 mg/day). If tubular secretion is not
saturable at higher concentrations or in the presence offamotidine exceeded GFR by approximately threefold
and was concentration independent. Previous studies of inhibitors of p-glycoprotein then the measurement of
tubular clearance after administration of a low-dose infu-the tubular clearance of famotidine in humans are lim-
ited. Following intravenous bolus administration (20 mg sion may be used as an index of cationic secretion. Poten-
tial applications of the PAH sequential infusion and fa-over 2 min) in seven patients with CCr of 116 6 10 mL/
min/1.73 m2, total tubular clearance was approximately motidine tubular clearance methods include assessment
of drug and disease-related effects on anionic and cat-286 mL/min/1.73 m2 [45].
The rate of tubular secretion of famotidine increased ionic tubular secretion, respectively, in patients with vari-
ous degrees of renal insufficiency.linearly with the plasma concentrations achieved in the
present study. Prior studies in animal models suggested
that the rate of secretion was saturable with Km and Tmax ACKNOWLEDGMENTS
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